About me

Sandhya Prashad, MD is a board-certified psychiatrist specializing in interventional modalities for treatment resistant disorders with a particular interest and expertise in ketamine therapy. She completed both medical school and psychiatry residency at Baylor College of Medicine. She has been in private practice in the Houston area since 2011 and has been utilizing intravenous ketamine since 2016. She has personally administered over 9,000 treatments with ketamine or esketamine. She is the founder and medical director of Sandhya J. Prashad, MD, Houston Ketamine Therapeutics, and Houston TMS Therapeutics. Dr. Prashad is involved on an international level with furthering awareness and education regarding the safe and effective use of ketamine. She is a founder, the former secretary and the current president of the American Society of Ketamine Physicians, Psychotherapists and Practitioners (ASKP3, www.ASKP.org) Dr. Prashad presents frequently on a national level both to the public and to other physicians regarding the use of ketamine for psychiatric disorders. She also serves on several advisory panels for ketamine related research. She is also a faculty member of the Integrative Psychiatry Institute where she assisted in developing the curriculum for the ketamine medical provider training. She also actively lectures and mentors others through the program, which was designed to establish the gold standard in ketamine competency for healthcare providers.

Dr. Prashad has been appointed as a clinical assistant professor at Baylor College of Medicine in the Menninger Department of Psychiatry and Behavioral Sciences where she assists in education of residents and medical students regarding the use of ketamine, esketamine and TMS in clinical practice. Dr. Prashad was also named one of Houston’s Top Doctors by H Texas Magazine for 2017, 2018, 2019 and 2020. She continues to work to expand her practice to include evidence based interventional treatments as they become available, and has a particular interest in expanding access to these treatments.